Oz Adler

Autism CBD Trial Enrolls Children: This Israeli Co. Is Making Headway In New Treatments

Next-Gen Psychedelics Companies SciSparc And Clearmind Collaboration File 3 Patents

This Company Leads The Way In Cannabinoid Treatment Innovation With New Patent

Next-Gen Psychedelics Companies SciSparc And Clearmind Collaboration File 3 Patents

This Company Leads The Way In Cannabinoid Treatment Innovation With New Patent

This Pharma Company Is Working With Israeli Medical Center To Research And Treat Autism With CBD

SciSparc Signs Non-Binding LOI To Sell A 50% Interest In Its Subsidiary That Owns Wellution

This Pharma Company Is Working With Israeli Medical Center To Research And Treat Autism With CBD

SciSparc Signs Non-Binding LOI To Sell A 50% Interest In Its Subsidiary That Owns Wellution

SciSparc And Clearmind Partnership Yields 3rd Patent Application For The Treating Of Obesity And Metabolic Syndromes

SciSparc To Acquire One Of Top Sellers Of Food Supplements, Cosmetics And Hemp-Based Products On Amazon

Oz Adler Recent News

SciSparc Awaiting Approval For Phase IIb Study Of Its Dronabinol Based Drug For Treatment Of Tourette Syndrome

SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, has successfully completed the development of its top-tier drug candidate SCI-110 to be used in its upc

SciSparc & Clearmind Medicine Team Up On Patent For Psychedelic Combination To Treat Cocaine Addiction

SciSparc Ltd. (NASDAQ: SPRC) collaboration with Clearmind Medicine Inc. (OTCPK:CMNDF) (CSE:CMND) (FSE:CWY0) resulted in the filing of a provisional patent application related to treating cocaine addiction.